论文部分内容阅读
目的观察云克治疗Graves眼病(GO)所致突眼的疗效。方法选取2009年12月—2013年9月于武汉市中心医院核医学科确诊的GO所致突眼患者85例,均予以云克治疗。观察患者临床疗效及不良反应情况。结果患者显效11例(12.9%),有效58例(68.3%),无效16例(18.8%),总有效率为81.2%。轻度突眼患者总有效率高于中度突眼患者及重度突眼患者,中度突眼患者总有效率高于重度突眼患者,差异均有统计学意义(P<0.05);不同病程突眼患者临床疗效比较,差异无统计学意义(P>0.05);治疗时及疗程结束后血常规、肝肾功能均未见异常,亦未发现其他严重不良反应。结论云克治疗GO所致突眼的疗效显著,方法简便,无严重不良反应,安全性高。
Objective To observe the curative effect of Yunke on exophthalmos caused by Graves ophthalmopathy (GO). Methods Eighty-five patients with exophthalmos were selected from December 2009 to September 2013 in the Department of Nuclear Medicine of Wuhan Central Hospital. All patients were treated with Yunke. Observed the clinical efficacy and adverse reactions. Results The patients were markedly effective in 11 cases (12.9%), effective in 58 cases (68.3%), ineffective in 16 cases (18.8%), the total effective rate was 81.2%. The total effective rate of patients with mild exophthalmia was higher than that of moderate exophthalmos patients and severe exophthalmos patients. The total effective rate of patients with moderate exophthalmos was higher than that of severe exophthalmos patients (P <0.05) There was no significant difference in the clinical efficacy between patients with exophthalmos (P> 0.05). No abnormalities in blood, liver and kidney function were found after treatment and after the end of treatment, and no other serious adverse reactions were found. Conclusion The efficacy of Yunke in the treatment of exophthalmos caused by GO is remarkable, the method is simple, without serious adverse reactions and high in safety.